Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to determine whether paricalcitol is safe and effective
compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney
disease.